Abstract
Objective Squamous cell carcinomas (SCC) are the most common malignancies in the oral mucosa; these carcinomas have been preceded by potentially malignant oral disorders (PMODs), mostly oral leukoplakia (OL). No specific biomarker has been widely accepted for predicting the risk of malignant transformation of PMODs. The aim of this study was to develop an accurate prediction model for the malignant transformation of OL using clinical variables and candidate biomarkers. Materials and methods To achieve this goal, 10 candidate biomarkers that had previously been reported as useful molecules were investigated: P53, Ki-67, P16, β-catenin, c-jun, c-met, insulin like growth factor II mRNA-binding protein (IMP-3), cyclooxygenase (COX-2), podoplanin (PDPN) and carbonic anhydrase 9 (CA9). For this study, malignant transformed (n = 22, median interval of malignant conversion: 3.3 years) and untransformed (n = 138) OL specimens with median follow-up period of 11.3 years (range: 4.6–23.2 years) were immunohistochemically stained. Results Using univariate Cox regression analysis, all biomarkers were proven to be significant for predicting malignant transformation in OL. To reach the highest prediction accuracy, the repeated simulation was performed, revealing that the combination of P53 and CA9 with the clinical factors including age and degree of dysplasia achieved the highest prediction accuracy. We constructed a nomogram with the identified prognostic factors for predicting the 5-, 10-, and 15-year progression free survival of OL. Conclusions The proposed nomogram may be useful for the accurate and individual prediction of the transformation to SCC in OL patients and may help clinicians offer appropriate treatments and follow up.
| Original language | English |
|---|---|
| Pages (from-to) | 132-139 |
| Number of pages | 8 |
| Journal | Oral Oncology |
| Volume | 72 |
| DOIs | |
| Publication status | Published - 2017 Sep 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oral Surgery
- Oncology
- Cancer Research
Cite this
}
Nomogram for risk prediction of malignant transformation in oral leukoplakia patients using combined biomarkers. / Zhang, Xianglan; Kim, Ki Yeol; Zheng, Zhenlong; Bazarsad, Shadavlonjid; Kim, Jin.
In: Oral Oncology, Vol. 72, 01.09.2017, p. 132-139.Research output: Contribution to journal › Article
TY - JOUR
T1 - Nomogram for risk prediction of malignant transformation in oral leukoplakia patients using combined biomarkers
AU - Zhang, Xianglan
AU - Kim, Ki Yeol
AU - Zheng, Zhenlong
AU - Bazarsad, Shadavlonjid
AU - Kim, Jin
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Objective Squamous cell carcinomas (SCC) are the most common malignancies in the oral mucosa; these carcinomas have been preceded by potentially malignant oral disorders (PMODs), mostly oral leukoplakia (OL). No specific biomarker has been widely accepted for predicting the risk of malignant transformation of PMODs. The aim of this study was to develop an accurate prediction model for the malignant transformation of OL using clinical variables and candidate biomarkers. Materials and methods To achieve this goal, 10 candidate biomarkers that had previously been reported as useful molecules were investigated: P53, Ki-67, P16, β-catenin, c-jun, c-met, insulin like growth factor II mRNA-binding protein (IMP-3), cyclooxygenase (COX-2), podoplanin (PDPN) and carbonic anhydrase 9 (CA9). For this study, malignant transformed (n = 22, median interval of malignant conversion: 3.3 years) and untransformed (n = 138) OL specimens with median follow-up period of 11.3 years (range: 4.6–23.2 years) were immunohistochemically stained. Results Using univariate Cox regression analysis, all biomarkers were proven to be significant for predicting malignant transformation in OL. To reach the highest prediction accuracy, the repeated simulation was performed, revealing that the combination of P53 and CA9 with the clinical factors including age and degree of dysplasia achieved the highest prediction accuracy. We constructed a nomogram with the identified prognostic factors for predicting the 5-, 10-, and 15-year progression free survival of OL. Conclusions The proposed nomogram may be useful for the accurate and individual prediction of the transformation to SCC in OL patients and may help clinicians offer appropriate treatments and follow up.
AB - Objective Squamous cell carcinomas (SCC) are the most common malignancies in the oral mucosa; these carcinomas have been preceded by potentially malignant oral disorders (PMODs), mostly oral leukoplakia (OL). No specific biomarker has been widely accepted for predicting the risk of malignant transformation of PMODs. The aim of this study was to develop an accurate prediction model for the malignant transformation of OL using clinical variables and candidate biomarkers. Materials and methods To achieve this goal, 10 candidate biomarkers that had previously been reported as useful molecules were investigated: P53, Ki-67, P16, β-catenin, c-jun, c-met, insulin like growth factor II mRNA-binding protein (IMP-3), cyclooxygenase (COX-2), podoplanin (PDPN) and carbonic anhydrase 9 (CA9). For this study, malignant transformed (n = 22, median interval of malignant conversion: 3.3 years) and untransformed (n = 138) OL specimens with median follow-up period of 11.3 years (range: 4.6–23.2 years) were immunohistochemically stained. Results Using univariate Cox regression analysis, all biomarkers were proven to be significant for predicting malignant transformation in OL. To reach the highest prediction accuracy, the repeated simulation was performed, revealing that the combination of P53 and CA9 with the clinical factors including age and degree of dysplasia achieved the highest prediction accuracy. We constructed a nomogram with the identified prognostic factors for predicting the 5-, 10-, and 15-year progression free survival of OL. Conclusions The proposed nomogram may be useful for the accurate and individual prediction of the transformation to SCC in OL patients and may help clinicians offer appropriate treatments and follow up.
UR - http://www.scopus.com/inward/record.url?scp=85025075488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025075488&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2017.07.015
DO - 10.1016/j.oraloncology.2017.07.015
M3 - Article
VL - 72
SP - 132
EP - 139
JO - Oral Oncology
JF - Oral Oncology
SN - 1368-8375
ER -